Review NEURELIS COMPLETES PRE-IND MEETING WITH FDA TO ESTABLISH CLINICAL DEVELOPMENT PROGRAM FOR NRL-4 IN THE TREATMENT OF ACUTE AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR 1 MANIA IN ADULTS adminNovember 23, 2020240 Views0 SAN DIEGO, CA – November 23, 2020 – Neurelis, Inc., announced today that it has concluded a pre-Investigational New Drug (IND) Application meeting with the U.S.… Read More